BNRNasdaqServices-Medical Laboratories
Burning Rock Biotech Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026
$12.29−0.61 (-4.73%)
Close on Oct 19, 2026
Burning Rock Biotech Ltd revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| In-hospital business [Member] | CN¥224.04M | CN¥224.49M | CN¥188.70M | CN¥175.30M | CN¥165.12M | CN¥117.87M | CN¥87.68M | CN¥33.19M | 41.5% | -0.2% |
| Central laboratory business [Member] | CN¥159.99M | CN¥175.65M | CN¥232.81M | CN¥314.77M | CN¥319.35M | CN¥297.34M | CN¥276.25M | CN¥161.46M | 29.7% | -8.9% |
| Pharma research and development services [Member] | CN¥155.54M | CN¥115.68M | CN¥115.92M | CN¥73.17M | CN¥23.39M | CN¥14.69M | CN¥17.75M | CN¥14.22M | 28.8% | +34.5% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Service [Member] | CN¥316.11M | CN¥290.74M | CN¥345.03M | CN¥391.55M | CN¥342.47M | CN¥311.18M | CN¥292.52M | CN¥180.19M | 58.6% | +8.7% |
| Product [Member] | CN¥223.46M | CN¥225.08M | CN¥192.41M | CN¥171.69M | CN¥165.40M | CN¥118.72M | CN¥89.15M | CN¥28.68M | 41.4% | -0.7% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| China | – | CN¥510.24M | CN¥534.93M | CN¥553.30M | CN¥504.05M | CN¥429.90M | – | – | – | – |
| United States | – | CN¥5.58M | CN¥2.51M | CN¥9.93M | CN¥3.81M | CN¥0 | – | – | – | – |
From the segment and revenue-disaggregation notes of Burning Rock Biotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.